LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 50

Search options

  1. Article ; Online: Implementing a human factors approach to RCA

    Wiegmann, Douglas A / Wood, Laura J / Solomon, Demetrius B / Shappell, Scott A

    Journal of healthcare risk management : the journal of the American Society for Healthcare Risk Management

    2020  Volume 41, Issue 1, Page(s) 31–46

    Abstract: Root Cause Analysis and Action ( ... ...

    Abstract Root Cause Analysis and Action (RCA
    MeSH term(s) Humans ; Quality Improvement ; Root Cause Analysis ; Toxins, Biological
    Chemical Substances RCA II ; Toxins, Biological
    Language English
    Publishing date 2020-12-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2546719-0
    ISSN 2040-0861 ; 1074-4797
    ISSN (online) 2040-0861
    ISSN 1074-4797
    DOI 10.1002/jhrm.21454
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Editorial comment.

    Shappell, Scott B

    Urology

    2011  Volume 78, Issue 5, Page(s) 1119; author reply 1120

    MeSH term(s) Humans ; Male ; Prostatic Intraepithelial Neoplasia/pathology ; Prostatic Neoplasms/pathology
    Language English
    Publishing date 2011-11
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 192062-5
    ISSN 1527-9995 ; 0090-4295
    ISSN (online) 1527-9995
    ISSN 0090-4295
    DOI 10.1016/j.urology.2011.05.055
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Reply: To PMID 25443926.

    Brown, Jeffrey G / Shappell, Scott B

    Urology

    2014  Volume 84, Issue 5, Page(s) 1178

    MeSH term(s) Antigens, Neoplasm/genetics ; Antigens, Neoplasm/urine ; Humans ; Male ; Prostatic Neoplasms/urine ; RNA, Messenger/urine
    Chemical Substances Antigens, Neoplasm ; RNA, Messenger ; prostate cancer antigen 3, human
    Language English
    Publishing date 2014-11
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 192062-5
    ISSN 1527-9995 ; 0090-4295
    ISSN (online) 1527-9995
    ISSN 0090-4295
    DOI 10.1016/j.urology.2014.05.076
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Clinical utility of prostate carcinoma molecular diagnostic tests.

    Shappell, Scott B

    Reviews in urology

    2008  Volume 10, Issue 1, Page(s) 44–69

    Abstract: Instead of relying on serum prostate-specific antigen (PSA) to identify patients for prostate biopsy, new laboratory tests are needed that have improved specificity for prostate carcinoma (CaP), allow accurate classification of clinically insignificant ... ...

    Abstract Instead of relying on serum prostate-specific antigen (PSA) to identify patients for prostate biopsy, new laboratory tests are needed that have improved specificity for prostate carcinoma (CaP), allow accurate classification of clinically insignificant CaPs, allow for detection of clinically significant CaP in patients without elevated serum PSA, and allow for identification of aggressive forms of CaP, which may warrant adjunctive or even molecularly targeted therapy in the future. Over the last several years, high-throughput gene expression profiling and proteinomics have led to the identification of genes and proteins that are specifically overexpressed in CaP. Molecular diagnostic techniques readily translated to the clinical laboratory have been incorporated into the development of new tests based on these novel molecular alterations in CaP. Some of these tests already have well-documented clinical utility, such as in facilitating prostate biopsy decisions, and are routinely available. The current review focuses on the biological, clinical, and laboratory aspects of the most promising of these current and near-future molecular CaP tests.
    Language English
    Publishing date 2008-05-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2108895-0
    ISSN 2153-8182 ; 1523-6161
    ISSN (online) 2153-8182
    ISSN 1523-6161
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Reply: To PMID 25443926.

    Brown, Jeffrey G / Rigler, Wayne / Shappell, Scott B

    Urology

    2014  Volume 84, Issue 5, Page(s) 1179–1180

    MeSH term(s) Antigens, Neoplasm/genetics ; Antigens, Neoplasm/urine ; Humans ; Male ; Prostatic Neoplasms/urine ; RNA, Messenger/urine
    Chemical Substances Antigens, Neoplasm ; RNA, Messenger ; prostate cancer antigen 3, human
    Language English
    Publishing date 2014-11
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 192062-5
    ISSN 1527-9995 ; 0090-4295
    ISSN (online) 1527-9995
    ISSN 0090-4295
    DOI 10.1016/j.urology.2014.05.077
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Reflex PCA3 messenger ribonucleic acid testing: validation of postbiopsy urine samples and correlation with prostate biopsy findings in ∼2000 patients.

    Brown, Jeffrey G / Fulmer, John R / Romano, Javier / Pownell, John / Rigler, Wayne / Wirtshafter, Amery / Sarno, Mark / Shappell, Scott B

    Urology

    2014  Volume 84, Issue 5, Page(s) 1172–1180

    Abstract: Objective: To validate post-transrectal ultrasonography (TRUS) prostate biopsy (bx) urine samples for PCA3 messenger ribonucleic acid testing, including correlation of PCA3 score with concurrent bx findings.: Methods: From July 2008 to July 2010, ... ...

    Abstract Objective: To validate post-transrectal ultrasonography (TRUS) prostate biopsy (bx) urine samples for PCA3 messenger ribonucleic acid testing, including correlation of PCA3 score with concurrent bx findings.
    Methods: From July 2008 to July 2010, 2015 patients had urine collected immediately after a TRUS-guided prostate bx. Excluded were men with history of prostate carcinoma (CaP), <6 or ≥24 bx cores, and/or prostate-specific antigen (PSA) level ≥50 ng/mL, resulting in 1909 included men. PCA3 and PSA messenger ribonucleic acid were quantitated using transcription-mediated amplification. A PCA3 score of ≥35 was considered positive.
    Results: Mean and median ages were 66 years. Mean and median PSA levels were 6.7 and 5.1 ng/mL, respectively. Bxs were benign in 970 (50.8%), CaP in 726 (38%), high-grade prostatic intraepithelial neoplasia (HGPIN) in 124 (6.5%), and atypical in 89 (4.7%). PCA3 test was informative in 1887 (98.8%) patients. Means ± standard deviations (median) of PCA3 scores for benign, HGPIN, atypical, and CaP were 22.3 ± 27.9 (12.8), 37.6 ± 43.2 (24.1), 35.7 ± 36.2 (25.7), and 46.9 ± 48.1 (31.6; P <.05 benign vs CaP, benign vs HGPIN and atypical, HGPIN and atypical vs CaP). Sensitivity and specificity of PCA3 for CaP were 46.3% and 78.7%, respectively. CaP risk increased with progressively higher PCA3 score ranges from 14.8% for PCA3 <5 to 66.7% for PCA3 >100. Area under the curve (AUC) for the PCA3 receiver operating characteristics was not significantly different in men without prior bx (AUC = 0.716) compared with men with at least 1 prior nonpositive bx (AUC = 0.702).
    Conclusion: Post-TRUS bx urine is a valid sample for PCA3 testing. Patients with a negative bx and a positive PCA3 test may have a higher likelihood of unsampled CaP.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antigens, Neoplasm/genetics ; Antigens, Neoplasm/urine ; Biopsy ; Early Detection of Cancer ; Humans ; Male ; Middle Aged ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/urine ; RNA, Messenger/urine ; Retrospective Studies ; Risk Factors ; Sensitivity and Specificity ; Transcription, Genetic ; Ultrasonography
    Chemical Substances Antigens, Neoplasm ; RNA, Messenger ; prostate cancer antigen 3, human ; Prostate-Specific Antigen (EC 3.4.21.77)
    Language English
    Publishing date 2014-11
    Publishing country United States
    Document type Journal Article ; Validation Studies
    ZDB-ID 192062-5
    ISSN 1527-9995 ; 0090-4295
    ISSN (online) 1527-9995
    ISSN 0090-4295
    DOI 10.1016/j.urology.2014.05.067
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate cancer.

    Jiang, Ming / Shappell, Scott B / Hayward, Simon W

    Journal of cellular biochemistry

    2004  Volume 91, Issue 3, Page(s) 513–527

    Abstract: The development and maintenance of the prostate are dependent upon a complex series of interactions occurring between the epithelial and stromal tissues (Hayward and Cunha [2000]: Radiol. Clin. N. Am. 38:1-14). During the process of prostatic ... ...

    Abstract The development and maintenance of the prostate are dependent upon a complex series of interactions occurring between the epithelial and stromal tissues (Hayward and Cunha [2000]: Radiol. Clin. N. Am. 38:1-14). During the process of prostatic carcinogenesis, there are progressive changes in the interactions of the nascent tumor with its surrounding stroma and extracellular matrix. These include the development of a reactive stromal phenotype and the possible promotion, by stromal cells, of epithelial proliferation and loss of differentiated function (Hayward et al. [1996]: Ann. N. Y. Acad. Sci. 784:50-62; Grossfeld et al. [1998]: Endocr. Related Cancer 5:253-270; Rowley [1998]: Cancer Metastasis Rev. 17:411-419; Tuxhorn et al. [2002]: Clin. Cancer Res. 8:2912-2923). Many molecules play an as yet poorly defined role in establishing and maintaining a growth quiescent glandular structure in the adult. Peroxisome proliferator-activated receptor gamma (PPARgamma) is a candidate regulator of prostatic epithelial differentiation and may play a role in restricting epithelial proliferation. PPARgamma agonists are relatively non-toxic and have been used with limited success to treat some prostate cancer patients. We would propose that a more complete understanding of PPARgamma biology, particularly in the context of appropriate stromal-epithelial and host-tumor interactions would allow for the selection of patients most likely to benefit from this line of therapy. In particular, it seems reasonable to suggest that the patients most likely to benefit may be those with relatively indolent low stage disease for whom this line of therapy could be a useful additive to watchful waiting.
    MeSH term(s) Animals ; Arachidonic Acid/metabolism ; Cell Line, Tumor/drug effects ; Humans ; Ligands ; Lipoxygenase/metabolism ; Male ; Mice ; Models, Biological ; Prostaglandin-Endoperoxide Synthases/metabolism ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/physiopathology ; Prostatic Neoplasms/therapy ; Receptors, Cytoplasmic and Nuclear/agonists ; Receptors, Cytoplasmic and Nuclear/physiology ; Thiazolidinediones/pharmacology ; Thiazolidinediones/therapeutic use ; Transcription Factors/agonists ; Transcription Factors/physiology ; Xenograft Model Antitumor Assays
    Chemical Substances Ligands ; Receptors, Cytoplasmic and Nuclear ; Thiazolidinediones ; Transcription Factors ; Arachidonic Acid (27YG812J1I) ; Lipoxygenase (EC 1.13.11.12) ; Prostaglandin-Endoperoxide Synthases (EC 1.14.99.1)
    Language English
    Publishing date 2004-02-15
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S. ; Review
    ZDB-ID 392402-6
    ISSN 1097-4644 ; 0730-2312
    ISSN (online) 1097-4644
    ISSN 0730-2312
    DOI 10.1002/jcb.10770
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model.

    Kelavkar, Uddhav P / Parwani, Anil V / Shappell, Scott B / Martin, W David

    Neoplasia (New York, N.Y.)

    2006  Volume 8, Issue 6, Page(s) 510–522

    Abstract: The incidence and mortality of prostate cancer (PCa) vary greatly in different geographic regions, for which lifestyle factors, such as dietary fat intake, have been implicated. Human 15-lipoxygenase-1 (h15-LO-1), which metabolizes polyunsaturated fatty ... ...

    Abstract The incidence and mortality of prostate cancer (PCa) vary greatly in different geographic regions, for which lifestyle factors, such as dietary fat intake, have been implicated. Human 15-lipoxygenase-1 (h15-LO-1), which metabolizes polyunsaturated fatty acids, is a highly regulated, tissue-specific, lipid-peroxidating enzyme that functions in physiological membrane remodeling and in the pathogenesis of atherosclerosis, inflammation, and carcinogenesis. We have shown that aberrant overexpression of 15-LO-1 occurs in human PCa, particularly high-grade PCa, and in high-grade prostatic intraepithelial neoplasia (HGPIN), and that the murine orthologue is increased in SV40-based genetically engineered mouse (GEM) models of PCa, such as LADY and TRansgenic Adenocarcinoma of Mouse Prostate. To further define the role of 15-LO-1 in prostate carcinogenesis, we established a novel GEM model with targeted overexpression of h15-LO-1 in the prostate [human fifteen lipoxygenase-1 in mouse prostate (FLiMP)]. We used a Cre- mediated and a loxP-mediated recombination strategy to target h15-LO-1 specifically to the prostate of C57BL/6 mice. Wild-type (wt), FLiMP+/-, and FLiMP+/+ mice aged 7 to 21, 24 to 28, and 35 weeks were characterized by histopathology, immunohistochemistry (IHC), and DNA/RNA and enzyme analyses. Compared to wt mice, h15-LO-1 enzyme activity was increased similarly in both homozygous FLiMP+/+ and hemizygous FLiMP+/- prostates. Dorsolateral and ventral prostates of FLiMP mice showed focal and progressive epithelial hyperplasia with nuclear atypia, indicative of the definition of mouse prostatic intraepithelial neoplasia (mPIN) according to the National Cancer Institute. These foci showed increased proliferation by Ki-67 IHC. No progression to invasive PCa was noted up to 35 weeks. By IHC, h15-LO-1 expression was limited to luminal epithelial cells, with increased expression in mPIN foci (similar to human HGPIN). In summary, targeted overexpression of h15-LO-1 (a gene overexpressed in human PCa and HGPIN) to mouse prostate is sufficient to promote epithelial proliferation and mPIN development. These results support 15-LO-1 as having a role in prostate tumor initiation and as an early target for dietary or other prevention strategies. The FLiMP mouse model should also be useful in crosses with other GEM models to further define the combinations of molecular alterations necessary for PCa progression.
    MeSH term(s) Animals ; Arachidonate 15-Lipoxygenase/biosynthesis ; Disease Models, Animal ; Disease Progression ; Gene Expression Regulation, Neoplastic ; Humans ; Ki-67 Antigen/biosynthesis ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Prostate/metabolism ; Prostatic Intraepithelial Neoplasia/pathology ; Prostatic Neoplasms/enzymology
    Chemical Substances Ki-67 Antigen ; Arachidonate 15-Lipoxygenase (EC 1.13.11.33)
    Language English
    Publishing date 2006-06
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 1483840-0
    ISSN 1476-5586 ; 1522-8002
    ISSN (online) 1476-5586
    ISSN 1522-8002
    DOI 10.1593/neo.06202
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting.

    Shappell, Scott B / Fulmer, John / Arguello, David / Wright, Brian S / Oppenheimer, Jonathan R / Putzi, Mathew J

    Urology

    2009  Volume 73, Issue 2, Page(s) 363–368

    Abstract: Objectives: Multiple trials have shown the high specificity of urine prostate cancer gene 3 (PCA3) compared with serum prostate-specific antigen (PSA) for biopsy detection of prostate carcinoma. We characterized the patterns of use of PCA3 by community ... ...

    Abstract Objectives: Multiple trials have shown the high specificity of urine prostate cancer gene 3 (PCA3) compared with serum prostate-specific antigen (PSA) for biopsy detection of prostate carcinoma. We characterized the patterns of use of PCA3 by community urologists and determined the performance of PCA3 testing as a laboratory-developed test in a reference laboratory setting.
    Methods: The urine PCA3 and PSA mRNA levels after digital rectal examination were determined using transcription-mediated amplification. The cutoff for a positive PCA3 score (PCA3/PSA mRNA x 10(3)) were pre-established at > or = 35. The PCA3 results were correlated with the serum PSA level, previous biopsy history, and the prostate biopsy findings.
    Results: A total of 278 PCA3 tests were performed from December 2006 to June 2007. Of the PCA3 tested patients, 55.5% had previously undergone > or = 1 prostate biopsy; 92.7% had a PSA level > or = 2.5 ng/mL. The PCA3 test informative rate was 97.5%. For 50 samples that were also analyzed at a separate laboratory, concordance was achieved in 94%. The mean and median PCA3 score was 44.3 and 21.1, respectively. No correlation was found with the serum PSA level. The PCA3 test was negative in 16 of 19 patients with negative concurrent biopsy findings and positive in 8 of 11 with positive concurrent biopsy findings (sensitivity 72.7% and specificity 84.2%). Of 32 patients (70% with previous biopsy) who had undergone biopsy an average of 56 days after positive PCA3 test results, prostate carcinoma was detected in 41%.
    Conclusions: Urine PCA3 testing on the transcription-mediated amplification platform performed well as a laboratory-developed test. The high specificity of PCA3 was confirmed. In patients with elevated PSA levels and negative biopsy findings, PCA3 testing might be useful in choosing between repeat biopsy and more conservative follow-up.
    MeSH term(s) Antigens, Neoplasm/genetics ; Humans ; Laboratories ; Male ; Practice Patterns, Physicians' ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/urine ; RNA, Messenger/urine ; Urology
    Chemical Substances Antigens, Neoplasm ; RNA, Messenger ; prostate cancer antigen 3, human
    Language English
    Publishing date 2009-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 192062-5
    ISSN 1527-9995 ; 0090-4295
    ISSN (online) 1527-9995
    ISSN 0090-4295
    DOI 10.1016/j.urology.2008.08.459
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The Human Factors Analysis Classification System (HFACS) applied to health care.

    Diller, Thomas / Helmrich, George / Dunning, Sharon / Cox, Stephanie / Buchanan, April / Shappell, Scott

    American journal of medical quality : the official journal of the American College of Medical Quality

    2014  Volume 29, Issue 3, Page(s) 181–190

    Abstract: ... problems: (a) the use of root cause analysis is neither standardized nor reliable between organizations, (b ...

    Abstract In spite of efforts to improve patient safety since the 1999 report, To Error Is Human, recent studies have shown limited progress toward preventing serious error. Most hospitals use root cause analysis as a method of serious event investigation. The authors postulate that this method suffers from 4 problems: (a) the use of root cause analysis is neither standardized nor reliable between organizations, (b) hospitals focus on "who" did "what" rather than on "why" the error occurred, (c) the identified causes are often too nonspecific to develop actionable correction plans, and (d) a standardized nomenclature does not exist to allow analysis of recurring errors across the organization. This article describes the modification of the Human Factors Analysis Classification System based on James Reason's theory of error causation for use in health care. This method resolves the 4 deficiencies noted above. The authors' experience investigating 105 serious events over 2 years is described.
    MeSH term(s) Academic Medical Centers/statistics & numerical data ; Causality ; Humans ; Medical Errors/classification ; Medical Errors/statistics & numerical data ; Retrospective Studies ; Root Cause Analysis
    Language English
    Publishing date 2014-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1131772-3
    ISSN 1555-824X ; 1062-8606
    ISSN (online) 1555-824X
    ISSN 1062-8606
    DOI 10.1177/1062860613491623
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top